Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Eccles

Showing results (281-290 of 340) with videos related to

Pageof 34
Sort By:
Cancer Research|December 19, 2018
Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer RiskYaohua Yang, Lang Wu, Xiang Shu, et al.
Nature Communications|June 18, 2014
2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapyJingmei Li, Linda S Lindström, Jia N Foo, et al.
European Journal of Cancer (Oxford, England : 1990)|August 7, 2022
Incorporating progesterone receptor expression into the PREDICT breast prognostic modelIsabelle Grootes, Renske Keeman, Fiona M Blows, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2011
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testingPaul D P Pharoah, Rachel T Palmieri, Susan J Ramus, et al.
Journal of Medical Genetics|July 14, 2023
Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in IsraelHagai Levi, Shai Carmi, Saharon Rosset, et al.
Research Square|February 24, 2023
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survivalAnna Morra, Maartje A C Schreurs, Irene L Andrulis, et al.
European Urology|February 19, 2026
Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT StudyElizabeth K Bancroft, Elizabeth C Page, Jana McHugh, et al.
Cancer Medicine|July 4, 2023
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survivalAnna Morra, Maartje A C Schreurs, Irene L Andrulis, et al.
International Journal of Epidemiology|December 13, 2017
Body mass index and breast cancer survival: a Mendelian randomization analysisQi Guo, Stephen Burgess, Constance Turman, et al.
Breast Cancer Research : BCR|December 29, 2024
Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk predictionKristia Yiangou, Nasim Mavaddat, Joe Dennis, et al.
Pageof 34

Showing results (281-290 of 340) with videos related to

Sort By:
Pageof 34
Cancer Research|December 19, 2018
Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer RiskYaohua Yang, Lang Wu, Xiang Shu, et al.
Nature Communications|June 18, 2014
2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapyJingmei Li, Linda S Lindström, Jia N Foo, et al.
European Journal of Cancer (Oxford, England : 1990)|August 7, 2022
Incorporating progesterone receptor expression into the PREDICT breast prognostic modelIsabelle Grootes, Renske Keeman, Fiona M Blows, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2011
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testingPaul D P Pharoah, Rachel T Palmieri, Susan J Ramus, et al.
Journal of Medical Genetics|July 14, 2023
Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in IsraelHagai Levi, Shai Carmi, Saharon Rosset, et al.
Research Square|February 24, 2023
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survivalAnna Morra, Maartje A C Schreurs, Irene L Andrulis, et al.
European Urology|February 19, 2026
Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT StudyElizabeth K Bancroft, Elizabeth C Page, Jana McHugh, et al.
Cancer Medicine|July 4, 2023
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survivalAnna Morra, Maartje A C Schreurs, Irene L Andrulis, et al.
International Journal of Epidemiology|December 13, 2017
Body mass index and breast cancer survival: a Mendelian randomization analysisQi Guo, Stephen Burgess, Constance Turman, et al.
Breast Cancer Research : BCR|December 29, 2024
Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk predictionKristia Yiangou, Nasim Mavaddat, Joe Dennis, et al.
Pageof 34